Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine
Med Clin (Barc). 2021 Feb 26;156(4):166-171.
doi: 10.1016/j.medcli.2020.10.006.
Epub 2020 Nov 6.
[Article in
English,
Spanish]
Authors
Francisco Tejada Cifuentes
1
, Ángeles Lloret Callejo
2
, María José Tirado Peláez
2
, Olga Rubio Pulido
3
, Marta Ruiz-Morote Aragón
4
, Rocío Fernández Urrusuno
5
, María Isabel Muñoz Carreras
6
, María Isabel Méndez Esteban
7
, Victoria Maestre Sánchez
8
, Antonio García Bonilla
9
, José Manuel Paredero Dominguez
10
, Virginia Arroyo Pineda
11
, Esther Marco Tejón
12
, Gregorio Romero Candel
13
, Ana Isabel Fernández Marchante
14
, José Marco Del Rio
15
, Teresa Ortiz Martín
16
, Piedad López Sánchez
17
Affiliations
- 1 Gerencia de Atención Integrada de Albacete, Albacete, España. Electronic address: ftejada@sescam.jccm.es.
- 2 Gerencia de Atención Integrada de Albacete, Albacete, España.
- 3 Gerencia de Atención Primaria de Toledo, Toledo, España.
- 4 Gerencia de Atención Integrada. de Puertollano, Puertollano, España.
- 5 Distrito Sanitario Aljarafe, Sevilla, España.
- 6 Gerencia de Atención Integrada, Alcázar de San Juan, Alcázar de San Juan, España.
- 7 Área de Gestión Sanitaria Campo de Gibraltar, Cádiz, España.
- 8 Distrito Sanitario Condado Campiña, Huelva, España.
- 9 Área de Gestión Sanitaria Jerez, Costa Noroeste y Sierra de Cádiz, Jerez, España.
- 10 Gerencia de Atención Integrada, de Guadalajara, Guadalajara, España.
- 11 Gerencia de Atención Integrada Talavera de la Reina, Talavera de la Reina, España.
- 12 Gerencia de Atención Integrada de Cuenca, Cuenca, España.
- 13 Gerencia de Atención Integrada de Hellín, Hellín, España.
- 14 Gerencia de Atención Integrada de Villarrobledo, Villarrobledo, España.
- 15 Gerencia de Atención Integrada de Almansa, Almansa, España.
- 16 Gerencia de Atención Integrada de Valdepeñas, Valdepeñas, España.
- 17 Gerencia de Atención Integrada de Tomelloso, Tomelloso, España.
Abstract
Objective:
To analyze the incidence of Covid-19 in patients who are chronic users of hydroxychloroquine.
Patients and methods:
Cross-sectional retrospective observational multicenter study in health areas and districts from Castilla La-Mancha and Andalucia. Of the 4451 participants included in the first recruitment, 3817 with valid data were selected. The main variable of the study is the presence or absence of Covid-19 infection by clinical, serological or polymerase chain reaction diagnosis. Sociodemographic and clinical variables and treatment and concomitant comorbidities were recorded.
Results:
169 (4,45%) patients had Covid-19 infection, of which 12 (7.1%) died and 32 (18.9%) required hospital admission. Previous respiratory pathology was related to Covid-19 infection (P<.05). Maculopathy appears in 5.3% of patients and is significantly related to the dose of hydroxychloroquine consumed (P<.05).
Conclusion:
There is no relationship between chronic use of hydroxychloroquine and the incidence of Covid-19.
Keywords:
COVID-19; Coronavirus; Hidroxicloroquina; Hydroxychloroquine; Incidence; Incidencia; Tratamiento; Treatment.
Copyright © 2020 Elsevier España, S.L.U. All rights reserved.
Publication types
-
Multicenter Study
-
Observational Study
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
COVID-19 / complications
-
COVID-19 / diagnosis
-
COVID-19 / epidemiology*
-
COVID-19 Testing
-
Chronic Disease
-
Cross-Sectional Studies
-
Female
-
Humans
-
Hydroxychloroquine / therapeutic use*
-
Incidence
-
Lupus Erythematosus, Systemic / complications
-
Lupus Erythematosus, Systemic / drug therapy*
-
Male
-
Middle Aged
-
Prognosis
-
Protective Factors
-
Retrospective Studies
-
Risk Factors
-
Spain / epidemiology
Substances
-
Antirheumatic Agents
-
Hydroxychloroquine